15 results
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
. Diversity of subject populations also has become an area of increased focus, supported by FDA and legislative actions to establish requirements … for diversity action plans to ensure inclusion of underrepresented racial and ethnic populations in Phase 3 clinical trials. Phase 3 clinical studies
8-K
EX-10.5
gxbsku713xj779
27 Jul 23
Index to Financial Statements
5:28pm
10-K
2m3yl
31 Mar 21
Annual report
4:23pm
424B4
1xt43
11 Feb 21
Prospectus supplement with pricing info
12:00am
S-1
hb4s4a3
21 Jan 21
IPO registration
5:24pm
DRS
r6tt3u7 t7z
23 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next